by Madaline Spencer | Sep 4, 2026
Tammy Anderson, Executive Director, and Jenny Rose, Manager of Outreach and Management at Wake Up Narcolepsy, discuss the challenges of diagnosing narcolepsy and the profound impact the disorder can have on patients and their families. Both Ms. Anderson and Ms. Rose...
by Madaline Spencer | Sep 4, 2026
The US Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib) for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy....
by Madaline Spencer | Sep 3, 2026
The US Food and Drug Administration (FDA) has approved Mimrylo (rusfertide) for the treatment of adults with polycythemia vera (PV). PV is a condition characterized by an increased production of red blood cells. Affected people may also have excess white blood cells...
by Madaline Spencer | Sep 3, 2026
The US Food and Drug Administration (FDA) has approved Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET). ET is a condition characterized by an overproduction of platelets. Abnormal blood clotting is common in these...
by Madaline Spencer | Aug 31, 2026
The US Food and Drug Administration (FDA) has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). DM is a rare autoimmune condition that targets small blood vessels in the skin and muscle. Symptoms can include a red skin rash...
